Browse investments

Invest in Semnur Pharmaceuticals, Inc. on Stash

Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. The Company's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

To buy fractional shares of Semnur Pharmaceuticals, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: SMNR

Semnur Pharmaceuticals, Inc.

$0.71

-29.00%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

SMNR Performance Breakdown

Share Price

$0.71

Today's change

9.23%

Year to date change (YTD)

-91.65%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About SMNR

Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. The Company's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. It is developing SP-102 to address problems associated with corticosteroid products that are used in practice but not approved for epidural injection or the treatment of sciatica. SP-102 is a Phase III sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for use of potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is formulated without the use of preservatives and packaged in a pre-filled syringe.

Semnur Pharmaceuticals, Inc. Stock Ticker

SMNR

For more information

https://semnurpharma.com/investor-overview/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Semnur Pharmaceuticals, Inc. on Stash

Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. The Company's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

To buy fractional shares of Semnur Pharmaceuticals, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Semnur Pharmaceuticals, Inc. stock news

24/7 Wall Street

Goldman Sachs Sees a $2 Trillion Opportunity in Private Markets

Goldman Sachs (NYSE:GS | GS Price Prediction) is chasing a private markets opportunity measured in the trillions, and the firm has put a hard number on how much of it it wants to own – $750 billion in alternative assets under supervision by 2030.

1 day ago

CNBC

Delta launches 'basic business' fares without lounge access, seat selection

Delta is cutting up the front of the plane by introducing new classes, including "basic business." The cheaper Delta One fares won't come with airport lounge access or seat assignments.

1 day ago

Business Insider

OpenAI's most advanced AI model is breaking free — and colliding with Elon Musk's latest Grok release

OpenAI's new family of AI models is rolling out more widely after being under restrictions. The company plans to launch the new family of models, which includes Sol, this Thursday.

1 day ago

24/7 Wall Street

Broadcom's $200 Billion AI Opportunity Is Drawing New Interest From Investors

Broadcom (NASDAQ:AVGO | AVGO Price Prediction) is now being talked about in $200 billion increments.

1 day ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Semnur Pharmaceuticals, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Semnur Pharmaceuticals, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Semnur Pharmaceuticals, Inc.’s price can fluctuate throughout the course of each trading day—when you buy Semnur Pharmaceuticals, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Semnur Pharmaceuticals, Inc. stock price and the Semnur Pharmaceuticals, Inc. news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers one subscription plan: The Stash Plan.

The Stash Plan can help you reach different goals and offers a unique combination of financial accounts and features. This plan includes access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Semnur Pharmaceuticals, Inc. stock is complete, you'll officially be a shareholder of Semnur Pharmaceuticals, Inc.!